Evaluation in STEMI Patients Using FDY-5301
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2351 participants.
Also called NCT04837001
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,351 participants
- Sponsor
- Faraday Pharmaceuticals, Inc.
- Registry
-
NCT04837001 -
2021-001924-16
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Hungary, Israel, Poland, Portugal
- Registry status
- Completed
Technical summary
Registry record NCT04837001. Randomized; quadruple masking; primary purpose treatment. Start 2022-05-02 (actual); primary completion 2025-09-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation in STEMI Patients Using FDY-5301
- Acronym
- IOCYTE AMI-3
- Condition
- Acute Myocardial Infarction
- Condition
- STEMI
- Condition
- Percutaneous Coronary Revascularization
- Intervention (Drug)
- FDY-5301
- Intervention (Other)
- Placebo
- Lead sponsor
- Faraday Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct04837001- Content hash
f845f1184b9b14a8c3d8b0eceaaf60d1e3ae22793ca855b6317b2ce7ef238272